BNET Industries
Market Cap:$259.0M
Last Fiscal Year Sales:$44.4M
- Public
- US
Dow Jones Description
Specialty Pharmaceuticals Mfr Developing Abuse Deterrent Products
President, Chief Executive Officer and DirectorAndrew D Reddick
Number of Employees 15
Contact Information
616 N North Ct Ste 120
Palatine, Illinois 60067
(847) 705-7709
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
UPDATE 2-Acura says pain drug to miss June 30 approval date
-
Acura Pharmaceuticals ACUR Reports Mixed Q1 Results
-
Inside Wall Street
-
Company and People Notes: EMD Serono to Open Cambridge, MA, site; Akorn Appoints Interim CEO;...
-
Company and People Notes: King Announces Restructuring; SCOLR Pharma Appoints President and CEO; More...
News & Analysis
Filter by
acura pharmaceuticals inc. - All News and Analysis
Excess Oral Doses of Acurox® Tablets are Disliked by Subjects with a History of Opioid Abuse
Study Evaluating the Abuse Liability of Acurox ® Tablets Highlighted at the American Society of Addiction Medicineâs ASAM 40th Annual Medical-Scientific Conference ...
Wall Street Media Presents an Exclusive Video from Natixis Bleichroeder 2nd Annual Hidden Gems Conference
NEW YORK -- Wall Street Media presents an exclusive video of Mr. Joseph J. Corasanti, CEO of CONMED Corporation, (NASDAQ: CNMD) discussing their electro surgery products, and branching out into orthopedics. Please visit the following link to view the video: http://www.wsmco.com/show.aspx?1130_Up_and_Coming_Stocks Wall Street Media...
Robert Jones
Robert Jones has been appointed chief operating officer of Acura Pharmaceuticals Inc. He also becomes senior vice president of the company...
King Pharmaceuticals and Acura Pharmaceuticals Announce Completion of Patient Enrollment for Pivotal Phase III Clinical Trial Evaluating ACUROX™
Top-line Clinical Trial Results Expected by July 2008 NDA Submission Expected before end of 2008 BRISTOL, Tenn. & PALATINE, Ill. -- King Pharmaceuticals, Inc. (NYSE: KG) and Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) announced today the completion of patient enrollment for the pivotal Phase III clinical trial evaluating ACUROX[TM]...
PEOPLE
MANUFACTURERS Bausch & Lomb has named Gerald Ostrov as chairman and CEO. Most recently, Ostrov was company group chairman, worldwide vision care, for Johnson & Johnson from 1998-2006. Acura Pharmaceuticals has announced the appointment of George K. Ross to its board of directors and chairman of its Audit...
USPR, ACPH, UDTT, KDKN - OTCStockExchange.com Stock Alert.
M2 PRESSWIRE-1 February 2008-otcstockexchange.com: USPR, ACPH, UDTT, KDKN - OTCStockExchange.com Stock AlertC1994-2008 M2 COMMUNICATIONS LTD RDATE:01022008 Rochester, NY, February 1, 2007 - OTCStockExchange.com's "Mid-Day Stock Watch Alert" this afternoon are U.S. Precious Metals, Inc. (OTCBB: USPR), Acura Pharmaceuticals,...
OTCPicks.com Daily Market Movers Digest Midday Report for Friday, February 1st SPNG, RLTR, SCTN, ACPH, DDSS, CBGC.
M2 PRESSWIRE-1 February 2008-OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Friday, February 1st SPNG, RLTR, SCTN, ACPH, DDSS, CBGCC1994-2008 M2 COMMUNICATIONS LTD RDATE:01022008 Our Stocks to Watch today include SpongeTech Delivery Systems, Inc. (OTCBB: SPNG), ReelTime Rentals,...
Wall Street News Alert Issues Special Alert on AVRG! December 4, 2007
Wall Street News Alert's "stocks to watch" thismorning are: Advanced Resources Group (PINKSHEETS: AVRG), SynchronossTechnologies, Inc. (NASDAQ: SNCR), Acura Pharmaceuticals, Inc. (OTCBB: ACUR) and China Finance Online Co., Limited (NASDAQ: JRJC). The current price of gold is now trading around $800 per ounce, which meansinvestors should have Advanced Resources Group...
King, Acura in partnership for developing pain treatments
King Pharmaceuticals Inc. has entered into an agreement with Acura Pharmaceuticals Inc. to develop painkillers using the latter's Aversion technology. King will make an up-front cash payment to Acura of $30 million. King could be responsible for $28 million in additional payments to Acura pending achievement of certain milestones...
Black Diamond Brands Corp. Clears Blue Sky Laws in Approximately 38 States, Other Companies Announce Office Opening, Letter to Shareholders, Enter into Agreement to Sell Subsidiary, Secure Gross Proceeds, and Provide Operational Update.
M2 PRESSWIRE-31 July 2007-Stockguru.com: Black Diamond Brands Corp. Clears Blue Sky Laws in Approximately 38 States, Other Companies Announce Office Opening, Letter to Shareholders, Enter into Agreement to Sell Subsidiary, Secure Gross Proceeds, and Provide Operational UpdateC1994-2007 M2 COMMUNICATIONS LTD RDATE:31072007 ...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Andrew D Reddick | President, Chief Executive Officer and Director |
| Hoechst Marion Roussel | President and Coo of Marion Merrell Dow, Inc. |
| Peter A Clemens | Senior Vice President Investor and Media Relations, Chief Financial Officer and Secretary |
| Robert B. Jones | COO & Senior Vice President |
| Ron J. Spivey | Chief Scientific Officer |
| Albert W. Brzeczko | Vice President of Technical Affairs |
| Garth Boehm | PH.D. Vice President of Modified Release Dosage Form Development |
| James F. Emigh | Vice President of Marketing and Administration |
| Robert A. Seiser | Vice President, Corporate Controller and Treasurer |
| Immanuel Thangaraj | Managing Director and General Partner, Essex Woodlands Health Ventures |
| Greg Spinner | Director of Logistics and Special Projects |
| John G. Gilkay | Director of Ehs & Engineering |
| Richard J Markham | Director of Acura |
| Ron Leech | Senior Director Quality Assurance, Quality Control & Analytical Services |
| Argeris N. Karabelas | Director |
| Toby Wesson | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| George K. Ross | Chairman |
| Bruce F. Wesson | Board of Directors |
| William G. Skelly | Board of Directors |
| William Sumner | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | President, Chief Executive Officer and Director | Current |
| Acura Pharmaceuticals, Inc. | Board of Directors | Current |
| Burroughs Wellcome Co. - USA | Former | |
| Duke University | Master of Business Administration | Former |
| University of California | Bachelor of Arts Degree In Biology | Former |
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | President and Coo of Marion Merrell Dow, Inc. | Current |
| Acura Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | Senior Vice President Investor and Media Relations, Chief Financial Officer and Secretary | Current |
| Indiana University | MBA | Former |
| University of Notre Dame | B.B.A. Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | COO & Senior Vice President | Current |
| Opt-E-Scrip, Inc. | Chief Operating Officer | Former |
| Adolor Corporation | Coo | Former |
| Adolor Corporation | Vice President, Finance | Former |
| Opt-E-Scrip, Inc. | Vice President, Finance | Former |
| The University of North Carolina | M.B.A. | Former |
| Cornell University | B.S. | Former |
Ron Spivey has been Senior Scientific Advisor since January 1, 2009. He previously was Senior Vice President and Chief Scientific Officer since April, 2004. From June, 2003 to March, 2004 Dr. Spivey was President of Gibraltar Associates, a private company providing consulting services to the pharmaceutical industry relating to product research and development. From March, 1998 to May, 2002 he served as Vice President, Scientific Affairs for Alpharma / Purepac Pharmaceuticals. Additionally, Dr Spivey has served in a number of senior level scientific and leadership positions at Zenith Goldline Pharmaceuticals, Cima Labs Inc., Marion Merrell Dow, Burroughs Wellcome Company and Warner Chilcott Division of Warner Lambert. Dr. Spivey holds a BA degree from Indiana University and a Ph.D. degree in pharmaceutics from the University of Iowa.
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | Chief Scientific Officer | Current |
| Acura Pharmaceuticals, Inc. | Non-Executive Officer | Current |
| CIMA Labs Inc. | Former | |
| Burroughs Wellcome Co. - USA | Former | |
| The University of Iowa | Ph.D. Degree In Pharmaceutics | Former |
| Indiana University | BA Degree | Former |
Albert W. Brzeczko, Ph.D., has been Vice President, Technical Affairs since February 2009. From 1999 through 2009, Dr. Brzeczko was Vice President, Global Pharma New Product Development and Pharma Technologies for International Specialty Products, Inc., a contract services group specializing in the development of technologies for the bioenhancement of poorly soluble drugs. Prior to 1999, Dr. Brzeczko held various positions of increasing responsibility in pharmaceutical product development with UPM Pharmaceuticals, Banner Pharmacaps, Mylan Laboratories, and DuPont Merck. Dr. Brzeczko received a Bachelor of Science degree in biochemistry and a Ph.D. in pharmaceutical sciences from the University of Maryland.
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | Vice President of Technical Affairs | Current |
| University of Maryland | PH.D. In Pharmaceutical Sciences | Former |
| University of Maryland | Bachelor of Science Degree In Biochemistry | Former |
Garth Boehm, Ph.D., is our Vice President of Modified Release Dosage Form Development commencing May 11, 2009. From 2005 to April 2008, Dr. Boehm was Vice President of Product Development at Actavis Pharmaceuticals. From May 2004 to 2005 he served as Senior Vice President and Chief Scientific Officer for Able Laboratories, Inc., a pharmaceutical company and from October 1996 until April 2004 Dr. Boehm was Vice President, Product Development for Purepac Pharmaceutical Company. Dr. Boehm received a Bachelor of Science degree in physical and inorganic chemistry and a Ph.D. in physical and inorganic chemistry from the University of Adelaide, Australia. Age 59.
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | PH.D. Vice President of Modified Release Dosage Form Development | Current |
| Able Laboratories, Inc. | Chief Scientific Officer | Former |
| Able Laboratories, Inc. | Senior Vice President | Former |
| University Corp. | PH.D. In Physical and Inorganic Chemistry | Former |
| University Corp. | Bachelor of Science Degree In Physical and Inorganic Chemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | Vice President of Marketing and Administration | Current |
| Organon Inc. | Former | |
| George Mason University | MBA | Former |
| Washington State University | Bachelor of Pharmacy Degree | Former |
Bob Seiser has been Vice President, Treasurer and Corporate Controller since April 2004. Prior to that time, Mr. Seiser was the Company's Treasurer and Corporate Controller. From 1992 until joining the Company in March 1998, Mr. Seiser served as Treasurer and Corporate Controller of TC Manufacturing Co., Inc., a privately held company based in Evanston, Illinois, which through its various subsidiaries and divisions, manufactured generic pharmaceuticals, industrial coatings and flexible packaging. Bob is a Certified Public Accountant, was employed at KPMG Peat Marwick - Chicago, and earned a B.B.A. degree from Loyola University of Chicago.
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | Vice President, Corporate Controller and Treasurer | Current |
| Acura Pharmaceuticals, Inc. | Treasurer | Former |
| Loyola University Chicago | Bachelor of Business Administration Degree | Former |
Immanuel Thangaraj has been a director of Acura since December, 2002. Mr. Thangaraj has been a Managing Director of Essex Woodlands Health Ventures, a venture capital firm specializes in the healthcare industry, since 1997. He serves as a director of private companies. Prior to joining Essex Woodlands Health Ventures, he helped establish a telecommunication services company, for which he served as its CEO. Mr. Thangaraj holds a Bachelor of Arts and a Masters in Business Administration from the University of Chicago.
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | Managing Director and General Partner, Essex Woodlands Health Ventures | Current |
| Essex Woodlands | Current | |
| Med-Logics | Board of Directors | Current |
| Sound Id | Board of Directors | Current |
| Acura Pharmaceuticals, Inc. | Director | Current |
| Novacept Inc. | Investor | Current |
| Arch Venture Partners | Cfo | Former |
| Arch Venture Partners | Associate | Former |
| Booz Allen Hamilton, Inc. | management consultant | Former |
| Tufts University | Doctor of Medicine | Former |
| AVP, Inc. | Former | |
| Stanford University | Masters in Business Administration | Former |
| University of Chicago | Masters In Business Administration | Former |
| University of Chicago | Bachelor of Arts | Former |
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | Director of Logistics and Special Projects | Current |
| Special Projects, Inc. | Director | Current |
| Western Michigan University | BA Degree In Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Johnson & Johnson | Former | |
| University of Wisconsin | B.S. Degree In Chemical Engineering | Former |
| Organization | Position | Status |
|---|---|---|
| Care Capital, LLC | Partner | Current |
| Acura Pharmaceuticals, Inc. | Director of Acura | Current |
| Acura Pharmaceuticals, Inc. | Chairman of the Board | Current |
| Anacor Pharmaceuticals, Inc. | Board of Directors | Current |
| Marion Merrell Dow | Chief Executive Officer | Former |
| Aventis Pharma Limited | CEO | Former |
| Hoechst Marion Roussel | CEO | Former |
| Sanofi-Aventis | president | Former |
| Merck & Co. Inc. | President | Former |
| Marion Merrell Dow | President | Former |
| Merck & Co. Inc. | COO | Former |
| Marion Merrell Dow | Chief Officer | Former |
| Merck & Co. Inc. | senior vice president | Former |
| Merck Sharp & Dohme | Vice President of Marketing | Former |
| Merck Sharp & Dohme | Executive Director | Former |
| Merck Sharp & Dohme | Product Manager | Former |
| Marion Merrell Dow | Director | Former |
| Merck Sharp & Dohme | Director | Former |
| The Advisory Council | Board of Directors | Former |
| Acura Pharmaceuticals, Inc. | Board of Directors | Former |
| Purdue University | B.S. In Pharmacy and Pharmaceutical Sciences | Former |
| Organization | Position | Status |
|---|---|---|
| DPT Laboratories Ltd. | Former | |
| ILEX Oncology, Inc. | Former | |
| Edgewood College | BS Degree In Biochemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | Chairman | Current |
| Acura Pharmaceuticals, Inc. | Board of Directors | Current |
| Tier Technologies Inc. | Chief Financial Officer | Former |
| Tier Technologies Inc. | Executive Vice President | Former |
| Ernst & Ernst | Former | |
| Tier Technologies Inc. | Board Member | Former |
| The Ohio State University | Masters of Business Administration | Former |
| Organization | Position | Status |
|---|---|---|
| Care Capital, LLC | Executive Director | Current |
| Vanda Pharmaceuticals Inc. | Co-Founder | Current |
| Care Capital, LLC | Partner | Current |
| Skyepharma, Inc. | Non-Executive Director | Current |
| Fox Chase Cancer Center | Trustee | Current |
| Skyepharma, Inc. | Non-Executive Director, Chairman of the Remuneration Committee | Current |
| SkyePharma PLC | Chairman | Current |
| Human Genome Sciences, Inc. | Chairman | Current |
| Vanda Pharmaceuticals Inc. | Director and Chairman of the Board | Current |
| NitroMed, Inc. | Chairman | Current |
| Acura Pharmaceuticals, Inc. | Director | Current |
| Fox Chase Cancer Center | Board of Directors | Current |
| Human Genome Sciences, Inc. | Director | Current |
| Minster Pharmaceuticals Plc | Director | Current |
| Waltham Diabetes Center, LLC | Director | Current |
| Anadys Pharmaceuticals, Inc. | Board of Directors | Current |
| Renovo Plc | Director | Current |
| Massachusetts General Hospital | Member | Current |
| Fox Chase Cancer Center | Trustee | Current |
| Novartis AG | CEO | Former |
| GlaxoSmithKline Plc | Executive Vice President, Worldwide Pharmaceuticals | Former |
| SmithKline Beecham Corporation | Executive Vice President | Former |
| Strategic Marketing, Inc. | Executive Vice President | Former |
| Novartis AG | Founder | Former |
| Novartis BioVenture Fund | Founder | Former |
| NitroMed, Inc. | Interim President, Chief Executive Officer and Director | Former |
| Novartis AG | Head of Healthcare | Former |
| Philadelphia University | Trustee | Former |
| Novartis BioVenture Fund | Chairman | Former |
| Epigenesis Pharmaceuticals, LLC | Chairman | Former |
| SkyePharma PLC | Director | Former |
| NitroMed, Inc. | Director | Former |
| Vanda Pharmaceuticals Inc. | Director | Former |
| University of New Hampshire | B.S. In Biochemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Galen Partners | General Partner | Current |
| Colgate University | Trustee | Current |
| Essential Patient Recruitment | Board of Directors | Current |
| Derma Sciences, Inc. | Board of Directors | Current |
| Acura Pharmaceuticals, Inc. | Board of Directors | Current |
| Anderol, Inc. | Board of Directors | Current |
| Essential Group, Inc. | Board of Directors | Current |
| QMed, Inc. | Board of Directors | Current |
| Daou Systems, Inc. | Director | Current |
| Great Lakes Chemical Corp | Board of Directors | Current |
| Chemtura Corporation | Board of Directors | Current |
| Smith Barney | Senior Vice President | Former |
| Smith Barney | Managing Director | Former |
| QMed, Inc. | Chairman of The Board | Former |
| Smith Barney | Chairman, Corporate Finance | Former |
| Columbia University | M.B.A. | Former |
| Colgate University | Bachelor of Arts Degree | Former |
| Colgate University | graduate | Former |
| Organization | Position | Status |
|---|---|---|
| QMed, Inc. | Board of Directors | Current |
| Acura Pharmaceuticals, Inc. | Director | Current |
| Derma Sciences, Inc. | Board of Directors | Current |
| Columbia University | Masters of Business Administration | Former |
| Colgate University | Bachelor of Arts Degree | Former |
Bill Skelly has been a director of Acura since May, 1996 and was Chairman of Acura from October, 1996 through June, 2000. Since 1990, Mr. Skelly has served as Chairman, President and Chief Executive Officer of Central Biomedia, Inc. and its subsidiary Sera, Inc. These companies are involved in the animal health industry including veterinary biologicals and custom manufacturing of animal sera products. From 1985 to 1990, Mr. Skelly served as President of Martec Pharmaceutical, Inc., a distributor and manufacturer of human generic prescription pharmaceuticals. Mr. Skelly holds a B.A. degree from Michigan State University and a Masters in Business Administration from the University of Missouri-Kansas City.
| Organization | Position | Status |
|---|---|---|
| Acura Pharmaceuticals, Inc. | Board of Directors | Current |
| Martec Pharmaceutical, Inc. | President | Former |
| Acura Pharmaceuticals, Inc. | Chairman | Former |
| University of Missouri-Kansas City | Masters In Business Administration | Former |
| Michigan State University | B.A. Degree | Former |
Bill Sumner has been a director of Acura since August, 1997. From 1974 until his retirement in 1995, Mr. Sumner held various positions at Hoechst-Roussel Pharmaceuticals, Inc., a manufacturer and distributor of pharmaceutical products, including Vice President and General Manager, Dermatology Division from 1991 through 1995, Vice President, Strategic Business Development, from 1989 to 1991 and Vice President, Marketing from 1985 to 1989. Since his retirement from Hoechst-Roussel Pharmaceuticals, Inc. Mr. Sumner has been a consultant to the pharmaceutical industry. Mr. Sumner holds a B.A. degree from Montclair State University and a Master of Arts from the University of Virginia.
| Organization | Position | Status |
|---|---|---|
| Strategic Business Development Inc | Vice President | Current |
| Acura Pharmaceuticals, Inc. | Board of Directors | Current |
| University of Virginia | Master of Arts | Former |
| University of Virginia | B.A. Degree | Former |
| Montclair State University | B.A. Degree | Former |
Industry Transcripts by Seeking Alpha
-
BMP Sunstone Corporation Q1 2009 Earnings Call Transcript
on Jun 30, 2009about BJGP
-
Matrixx Initiatives, Inc., F4Q09 (Qtr End 03/31/09) Earnings Call Transcript
on May 12, 2009about MTXX
-
King Pharmaceuticals Inc., Q1 2009 Earnings Call Transcript
on May 11, 2009about KG
-
Flamel Technologies SA Q1 2009 Earnings Call Transcript
on May 11, 2009about FLML
-
Sucampo Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
on May 08, 2009about SCMP
Glass Door
IndustryTop Rated
- AstraZeneca's Seroquel Research Director Confessed to Sex-for-Studies Affairs 17 votes
- Forest Labs' Lexapro Flap Over JAMA Article Will Likely Be Examined by the Feds 11 votes
- Medarex Execs Got 10% Pay Raise Despite Delivering Nothing 11 votes
- Schering CEO Hassan Has $59 Million Buyout Agreement in Merck Merger 10 votes
- Gilead Whistleblower Suit: A Bullet Dodged 10 votes
